Novartis Investigative Site

Dudley, West Midlands DY1 2HQ

1 studies enrolling now · 12 studies all time

What they study most

Acute Heart Failure, Atopic Dermatitis, Chronic Heart Failure With Reduced Ejection Fraction, Heart Failure With Reduced Ejection Fraction, Hidradenitis Suppurativa, Moderate to Severe Nail Psoriasis, Moderate to Severe Palmoplantar Psoriasis, Moderate to Severe Plaque-type Psoriasis, Psoriasis, Psoriatic Arthritis

Studies at this site

• Platform Study to Evaluate the Efficacy and Safety of Investigational Compound(s) in Patients With Moderate to Severe Atopic Dermatitis — Recruiting now
• Extension Study to Assess Effects of Non-interrupted Versus Interrupted and Long Term Treatment of Two Dose Regimes of Secukinumab in Subjects With Hidradenitis Suppurativa — Running, not enrolling
• Study of Efficacy and Safety of Two Secukinumab Dose Regimens in Subjects With Moderate to Severe Hidradenitis Suppurativa (HS) — Completed
• A Study to Assess the Safety and Efficacy of ZPL389 in Patients With Moderate to Severe Atopic Dermatitis — Stopped early
• Efficacy at 24 Weeks With Long Term Safety, Tolerability and Efficacy up to 5 Years of Secukinumab in Patients of Active Psoriatic Arthritis — Completed
• Study of Secukinumab With 2 mL Pre-filled Syringes — Completed
• Safety and Tolerability During Open-label Treatment With LCZ696 in Patients With CHF and Reduced Ejection Fraction — Completed
• Extension Study of Secukinumab Prefilled Syringes in Subjects With Moderate to Severe Chronic Plaque-type Psoriasis Completing Preceding Psoriasis Phase III Studies With Secukinumab — Completed
• Efficacy, Safety and Tolerability of Serelaxin When Added to Standard Therapy in AHF — Completed
• Study of Safety, Tolerability, and Efficacy of Secukinumab in Subjects With Moderate to Severe Nail Psoriasis — Completed
• Study of Safety, Tolerability, and Efficacy of Secukinumab in Subjects With Moderate to Severe Palmoplantar Psoriasis — Completed
• This Study Will Evaluate the Efficacy and Safety of LCZ696 Compared to Enalapril on Morbidity and Mortality of Patients With Chronic Heart Failure — Stopped early